乌帕替尼缓释片治疗中国自身免疫介导炎症性疾病——特应性皮炎与类风湿关节炎及银屑病关节炎的药物经济学评价OA

Objective The pharmacoeconomic evaluation of Upadacitinib extended-release tablets was conducted for treatment of immune-mediated inflammatory disease in China,which include moderate to severe atopic dermatitis(AD),moderate to severe active rheumatoid arthritis(RA)),active psoriatic arthritis(PsA).Methods Three decision tree-Markov models were developed separately to evaluate the long-term costs and effectiveness of Upadacitinib compare with other common use drugs from the healthcare system perspective.Results Upadacitinib is more cost-effective compared with dupilumab injection in the treatment of AD and compared with adalimumab injection in the treatment of RA and PsA.Base case results showed the introduction of upadacitinib for the treatment of AD,RA,and PsA,yielded incremental Quality-Adjusted Life Years(QALYs)of 0.279,0.115,and 0.188,respectively.This incrementality in QALYs was concomitant with discernible cost reductions of ¥133 524(drug savings account for more than 99%of the total),¥5 090(drug savings account for 60%of the total),and ¥10 593(drug savings account for 90%of the total).Conclusion Upadacitinib evinced commendable therapeutic efficacy,low annul drug cost,expediency in oral administration.Through protracted simulation,it emerged as an agent heralding augmented improvements in the quality of life,as contrasted with extant clinical modalities.Simultaneously,it occasioned appreciable savings in the ambit of direct medical expenditures,encompassing pharmaceutical outlays.